Pharmacotherapy of hypercholesterolaemia: statins in clinical practice.

摘要: The objective of this article is to evaluate the roles lipid-lowering class 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in reducing cardiovascular events and review their mechanism action based on vitro vivo studies. clinical outcome 15 major trials has been critically reviewed summarised; all showed a high degree efficacy safety. Statins, either active or prodrug forms, are potent HMG-CoA reductase, have good absorption rate bioavailability depends lipophobicity concomitant use with meals. Abdominal discomfort most commonly reported adverse effect. Although incidence low, myopathy without rhabdomyolysis may be considered serious effect statins. combination statin gemfibrozil seems increase risk event, particularly patients renal impairment. Combination therapy several other agents, frequently admi...